Latest Breaking News On - Genentech - Page 6 : comparemela.com

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive

United statesAsia pacificAndrew carlsenFosun pharmaDavid freundelExchange commissionRoche groupAmerican cancer societyAmerican society of clinical oncologyClinical oncologyAnnual meetingNon small cell lung cancerNorth americaMedia releaseAnnual reportY shaped genmab

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) | Company Announcement

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) | Company Announcement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesFosun pharmaAcasunlimab duobodyJudith klimovskyAndrew carlsenAsia pacificDavid freundelRoche groupAmerican cancer societyExchange commissionAmerican society of clinical oncologyInvestigational acasunlimabClinical oncologyAnnual meetingExecutive vice presidentChief development officer

Research Finds In Utero Exposure to Ocrelizumab Not Associated With Increased Adverse Pregnancy, Infant Outcomes for Women With MS

Research Finds In Utero Exposure to Ocrelizumab Not Associated With Increased Adverse Pregnancy, Infant Outcomes for Women With MS
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.

Riley boveConsortium of multiple sclerosis centersMultiple sclerosis centers

Bowel cancer patient first in England to have personalised jab to fight disease

Bowel cancer patient first in England to have personalised jab to fight disease
chesterstandard.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chesterstandard.co.uk Daily Mail and Mail on Sunday newspapers.

United kingdomIain foulkesAmanda pritchardPeter johnsonHayley rolfeElliot pfebveCancer research united kingdomQueen elizabeth hospital birminghamVictoria kuneneCancer vaccine launch pad

Thousands to get cutting-edge personalised cancer vaccines in NHS trials

The latest vaccine technology is being used to create personalised treatments that target the DNA of patients specific tumours.

United kingdomUnited statesPeter johnsonAmanda pritchardElliot pfebveBiontech covidAmerican society of clinical oncologyRoche groupPatient elliotCancer vaccine launch padQueen elizabeth hospital birminghamAmerican societyClinical oncology